title: Tau PET imaging in Alzheimer's disease.
abstract: In several neurodegenerative diseases that are collectively called tauopathies, progressive accumulation of tau in the brain is closely associated with neurodegeneration and cognitive impairment. Noninvasive detection of tau protein deposits in the brain would be useful to diagnose tauopathies as well as to track and predict disease progression. Recently, several tau PET tracers including T807, THK-5117, and PBB3 have been developed and succeeded in imaging neurofibrillary pathology in vivo. For use of tau PET as a biomarker of tau pathology in Alzheimer's disease, PET tracers should have high affinity to PHF-tau and high selectivity for tau over amyloid-β and other protein deposits. PET tau imaging enables the longitudinal assessment of the spatial pattern of tau deposition and its relation to amyloid-β pathology and neurodegeneration. This technology could also be applied to the pharmacological assessment of anti-tau therapy, thereby allowing preventive interventions.
authors.affiliation: Department of Pharmacology, Tohoku University School of Medicine, 2-1, Seiryo-machi, Aoba-ku, Sendai, 9808575, Japan, nookamura@med.tohoku.ac.jp.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Okamura
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Harada
authors.forename: Shozo
authors.initials: S
authors.lastname: Furumoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Arai
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yanai
authors.forename: Yukitsuka
authors.initials: Y
authors.lastname: Kudo
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000378:metabolism*; D006801:Humans; D049268:Positron-Emission Tomography / Q000379:methods*; D011485:Protein Binding / Q000187:drug effects; D019275:Radiopharmaceuticals; D016875:tau Proteins / Q000378:metabolism*
chemical_list: C054369:MAPT protein, human; D019275:Radiopharmaceuticals; D016875:tau Proteins